Immunomodulator I Patent Portfolio Strengthened

Poolbeg Pharma PLC
20 September 2023

Poolbeg Pharma plc


Immunomodulator I Patent Portfolio Strengthened

Notice of allowance for patent grant in Japan


20 September 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it has received a notice of allowance from the Japanese Patent Office in relation to its Immunomodulator I patent application.


The claims deemed allowable cover a p38 MAPK (mitogen-activated protein kinase) inhibitor for use in the treatment of severe influenza in human patients and strengthens the Company's robust intellectual property in the territory. Grant of the application as a patent is expected upon completion of formalities.


Poolbeg has a worldwide licence for POLB 001 for all uses in humans and is developing a strong IP portfolio with patents in place, including Immunomodulator I and Immunomodulator II, covering the use of the class of p38 MAP kinase (mitogen-activated protein kinase) inhibitors for the treatment of severe influenza and hypercytokinaemia. The Company has also filed patent applications to expand its IP around POLB 001 and the use of p38 MAP kinase inhibitors in new disease areas, such as oncology. This enhances the value and attractiveness of POLB 001 to potential pharma partners.


Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, commented: "This milestone is a testament to the uniqueness of p38 MAPK inhibition as a potential blockbuster treatment for severe influenza. We are committed to continuing to strengthen the intellectual property protection of our portfolio of assets into new jurisdictions to increase their overall value to potential partners."



Immunomodulator I: Use of p38 MAPK inhibitors for the treatment of severe influenza

Immunomodulator II: Use of p38 MAPK inhibitors in combination with antiviral compounds for treatment of severe influenza, and the use of p38 MAPK inhibitors, alone or in combination with an antiviral agent, for the treatment of hypercytokinaemia


- Ends -




Poolbeg Pharma Plc

Jeremy Skillington, CEO

Ian O'Connell, CFO


+44 (0) 207 183 1499

Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)

Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)


+44 (0) 207 220 0500

Singer Capital Markets (Joint Broker)

Phil Davies, Sam Butcher


 +44 (0) 207 496 3000

J&E Davy (Joint Broker)

Anthony Farrell, Niall Gilchrist


+353 (0) 1 679 6363

Optimum Strategic Communications

Nick Bastin, Hana Malik, Vici Rabbetts 


+44 (0) 208 078 4357


About Poolbeg Pharma

Poolbeg Pharma specialises in the development of innovative medicines to address the unmet need in infectious and other prevalent diseases. Poolbeg Pharma has a disciplined portfolio approach to mitigate risk, accelerate drug development, and enhance investor returns. The Company simultaneously advances multiple programmes in cost-effective clinical trials, rapidly generating early human safety and efficacy data to enable early partnering / out-licensing, with the funds generated reinvested in the pipeline. Poolbeg Pharma also uses AI to interrogate human challenge trial data sets to quickly identify new targets and drugs, leading to faster development and greater commercial appeal.


The Company is targeting the growing infectious disease market. In the wake of the COVID-19 pandemic, infectious disease has become one of the fastest growing pharma markets and is expected to exceed $250bn by 2025. Through opportunistic identification of assets which complement Poolbeg Pharma's existing pipeline, the Company is progressing programmes in oncology and metabolic syndromes; adding disease areas with significant addressable markets.


With its initial assets from hVIVO plcan industry leading infectious disease and human challenge trials business, Poolbeg Pharma has access to knowledge, experience, and clinical data from over 20 years of human challenge trials. The Company is using these insights to acquire new assets as well as reposition clinical stage products, reducing spend and risk. Amongst its portfolio of exciting assets, Poolbeg Pharma has a small molecule immunomodulator for severe influenza and other acute inflammatory conditions (POLB 001) which produces a highly significant reduction in p38 MAP kinase driven cytokines in a clinical setting; a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The Company is progressing two Artificial Intelligence (AI) Programmes to add promising new assets to its pipeline as well as developing an Oral Vaccine Programme and an Oral Delivery Programme focussing on metabolic syndrome related diseases.  


For more information, please go to or follow us on Twitter and LinkedIn @PoolbegPharma.



This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
UK 100